143183-03-3

Basic information

• Product Name: (Benzothiazol-2-yl)-(Z)-2-trityloxyimino-2-(2-aminothiazole-4-yl)-thioacetate
• Synonyms: S-2-BENZOTHIAZOLYL(Z)-2-(2-AMINOTHIAZOL-4-YL)-2-TRITYLOXYIMINOTHIOACETATE;(Benzothiazol-2-yl)-(Z)-2-Trityimino-2-(2-Aminothiazol-4-yl)Thioac etate;2-mercaptobenzothiazolyl (z)-2-(2-aminothiazol-4-yl)-2-trityloxyiminoacetate;2-Mercaptobenzothiazolyl-(Z)-2-(2-Aminothiazol-4-Yl)-2-Trityloxyiminoacetate;S-2-BENZOTHIAZOLYL(Z)-2-(2-AMINOTHIAZOL-4-YL)-2-TRITYLOXYIMINOTHIOACETATE (BAEM);S-2-BENZOTHIAZOLYL(Z)-2-(2-AMINOTHIAZOL-4-YL)-2-TRITYLOXYIMINOTHIOACETATE(BAEM);(benzothiazol-2-yl)-(Z)-2-(2-aminothiazol-4-yl)thioacetate;2-mercaptobenzothiazolyl (z)-(2-aminothiazol-4-yl)-2-trityloxyiminoacetate
• CAS NO: 143183-03-3
• Molecular Formula: C₃₁H₂₂N₄O₂S₃
• Molecular Weight: 578.73
• Mol File: 143183-03-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 767.438 °C at 760 mmHg
• Flash Point: 417.932 °C
• Appearance: /
• Density: 1.367 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.721
• PKA: 0.90±0.10(Predicted)
• CAS DataBase Reference: (Benzothiazol-2-yl)-(Z)-2-trityloxyimino-2-(2-aminothiazole-4-yl)-thioacetate(CAS DataBase Reference)
• NIST Chemistry Reference: (Benzothiazol-2-yl)-(Z)-2-trityloxyimino-2-(2-aminothiazole-4-yl)-thioacetate(143183-03-3)
• EPA Substance Registry System: (Benzothiazol-2-yl)-(Z)-2-trityloxyimino-2-(2-aminothiazole-4-yl)-thioacetate(143183-03-3)

Safety Data

• Hazardous Substances Data: 143183-03-3(Hazardous Substances Data)

Usage

General Description

The chemical compound "(Benzothiazol-2-yl)-(Z)-2-trityloxyimino-2-(2-aminothiazole-4-yl)-thioacetate" is a complex organic molecule with a number of functional groups. It contains benzothiazole and amino-thiazole rings, as well as a trityloxyimino and thioacetate groups. The compound also features a Z-configuration, indicating a specific arrangement of the trityloxyimino and amino-thiazole groups. (Benzothiazol-2-yl)-(Z)-2-trityloxyimino-2-(2-aminothiazole-4-yl)-thioacetate may have potential applications in pharmaceuticals, materials science, or organic synthesis, due to its diverse and potentially valuable chemical structure.

InChI:InChI=1/C31H22N4O2S3/c32-29-33-25(20-38-29)27(28(36)40-30-34-24-18-10-11-19-26(24)39-30)35-37-31(21-12-4-1-5-13-21,22-14-6-2-7-15-22)23-16-8-3-9-17-23/h1-20H,(H2,32,33)/b35-27-

Upstream product

• 120-78-5 di(benzothiazol-2-yl)disulfide 
• 128438-01-7 (Z)-2-(2-aminothiazol-4-yl)-2-(triphenylmethoxyimino)acetic acid 
• 64485-82-1 (Z)-ethyl 2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetate 
• 76-83-5 trityl chloride 

Downstream Products

• 865411-26-3 N,N'-dicyclohexylethane-1,2-diamine salt of 7β-[2-(2-amino-4-thiazolyl)-2-((Z)-hydroxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid 
• 91832-40-5 cefdinir 
• 152401-10-0 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-methoxymethyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (S)-1-(2,2-dimethyl-propionyloxy)-ethyl ester 

Relevant articles and documents

Studies on Anti-MRSA parenteral cephalosporins I. Synthesis and antibacterial activity of 7

In order to improve the antibacterial activity of cefozopran (CZOP) against methicillin-resistant Staphylococcus aureus (MRSA), we initiated chemical modification to introduce a 2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-hydroxyimino acetyl group at the C-7 position and a 3- or 6-substituted imidazo[1,2-b]pyridazinium or 5-substituted imidazo[1,2-a]pyridinium group at the C-3' position. Although this approach successfully enhanced the anti-MRSA activity of CZOP two to eight times, a slight decrease in the activity against Gram-negative bacteria including Pseudomonas aeruginosa was involved. Among the novel derivatives, 3-(6-aminoimidazo [1,2-b]pyridazinium-1-yl) methyl-7β-[2-(5-amino -1,2,4-thiadiazol-3-yl) -2(Z)-hydroxyiminoacetamidol]-3-cephem-4-carboxylate (44a) showed an excellent balance of activity against MRSA and Gram-negative bacteria.

Process for the preparation of cephem prodrug esters

The invention relates to a process for the preparation of cephem prodrug esters of the formula: STR1 in which R1 is C1 -C5 -alkanoyloxy-C1 -C3 -alkyl or C1 -C5 -alkoxycarbonyloxy